Yinnuo Pharmaceutical-B (02591) completed enrollment and administration of the first patient in the Phase IB clinical trial of esupaglutide α for the treatment of adolescent obesity

Zhitongcaijing · 1d ago

Zhitong Finance App News, Yinnuo Pharmaceutical-B (02591) announced that according to the previous announcement, the company expects to launch a phase IB clinical trial of the Group's esupaglutide α to treat obesity in adolescents in July 2026. On July 28, 2026, the company successfully completed the enrollment and administration of the first patient in phase Ib of this clinical trial, and no safety issues or adverse effects were found during the observation period.